{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-003042","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.458314+00:00","generated_at":"2026-06-01T09:42:19.132759+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss","bullets":["Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).","28% of subjects on imdusiran + 24 weeks of IFN achieved HBsAg below lower limit of quantification with anti-HBs.","Imdusiran followed by VTP-300 maintained lower HBsAg levels; more subjects qualified to stop NA therapy and remain off therapy.","Additional on-treatment, follow-up, and NA discontinuation data to be presented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-003042","json":"https://secwatch.observer/filing/0001171843-24-003042.json","markdown":"https://secwatch.observer/filing/0001171843-24-003042.md","text":"https://secwatch.observer/filing/0001171843-24-003042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/0001171843-24-003042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/f8k_052224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:42:19.132759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}